Panitumumab Biosimilar, N297A Mutant | Catalog C012P.NA

Panitumumab Biosimilar, N297A Mutant. Panitumumab biosimilar CHO stable cell line is available for licensing to manufacture the panitumumab biosimilar protein. The research grade panitumumab biosimilar protein is for research use only (RUO). Recombinant human IgG2 isotype controls are available.

Product Specifications

Catalog No.	C012P.NA
Product Name	Panitumumab Biosimilar, N297A Mutant
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Anti-ErbB-1 Human Monoclonal Antibody, Anti-HER1 Human Monoclonal Antibody
Summary	Recombinant Humanized IgG2 Monoclonal Antibody.
Isotype	Human IgG2 N297A Mutant
Source/Host	Produced in the Panitumumab biosimilar CHO stable cell line.
Specificity	Specifically binds to the human EGFR, ErbB-1 and HER1.

Properties & Storage

Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by panitumumab.
Formulation	0.2 µM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Panitumumab, a fully anti-EGFR (epidermal growth factor receptor, EGF receptor, ErbB-1 and HER1 in humans) human monoclonal antibody, is used for the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS.